SHL has just completed an additional expansion of its Nan Kan 6 facility located in northern Taiwan to ensure that adequate production capacity can be maintained for its OEM/ODM customers. CNC, moulding and automation related production have been added to the facility, expanding on our support for these key in-house capabilities. In particular, this facility will house extensive CNC lines which will be utilised by SHL Automation to support production of automated testing and assembly equipment for our medical devices. In addition, these CNC lines will be utilised by SHL Technologies to support its growing need for precision machined components and modules.
Frank Isaksson, GM for Taiwan, commented on this growth stating: “Demand for autoinjectors continues to rise as the number of biologics coming to market steadily increases. The simple fact is that SHL will continue to expand our production capabilities over the next few years and will also find new ways to enhance our utilisation of current machinery, people and resources. Several of our biotechnology and pharmaceutical customers are now working with us on multiple projects. With continued expansion in Taiwan, our new facility in the US and future expansion in Europe, we will have the depth of capabilities and resources needed to maintain our leadership position in the auto injector market, including production of other drug delivery devices such as pen injectors and inhalers systems.”
SHL currently has six production facilities in Taiwan related to SHL Medical and plans to acquire space at two of its larger facilities as needed. Further expansion related to production facilities has also taken place in North America with SHL’s newest facility based in South Florida focusing on the final packaging and assembly of drug delivery devices, such as the Molly autoinjector. SHL will continue to develop additional in-house capabilities to further enhance the range of services we can offer to our clients.